ClinicalTrials.gg
Not yet recruitingNCT06164535Updated Dec 11, 2023

The Effects of DPPIs on Cognitive Function of Diabetic Patients

A Phase 4 interventional study of Control group and DPP-4 inhibitor group in Cognitive Impairment, sponsored by Beni-Suef University. Not yet recruiting at 1 site in Egypt. Open to participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Beni-Suef University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
45 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing metformin in Cognitive Dysfunction — 3 open to participants now, 4 under way, 2 of them phase 3. Metformin · Cognitive Dysfunction.

Planned enrollment
3rd of 10
105 · median 84
Started
2023
the only one that year
Phase 4
3 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Beni-Suef University

Among the 10 studies testing metformin in Cognitive Dysfunction, this one is the 3rd largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 9th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

3 of the 10 studies testing metformin in Cognitive Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 45 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing metformin in Cognitive Dysfunction, or all of them as a file.
02

Study summary

This is a single-center, randomized controlled clinical trial with a parallel-group design conducted at Minia University hospital.

Read the detailed description

All patients admitted to Diabetes clinics of Minia University Hospital, will be screened for the eligibility criteria.

diabetic patients (aged above 50 years) with uncontrolled diabetes on oral hypoglycemic drugs. 105 patients will be enrolled and randomized into three groups.

Group I=35 T2DM patients given DPP4Is Group II=35 T2DM patients given DPP4Is and metformin. Group III=35 patients will be given placebo (only adjust their drugs to control blood glucose level)

03

Conditions studied

  • Cognitive Impairment

Keywords

  • Cognitive
  • DPP-4 inhibitors
  • Diabetes
  • Depression
04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Type-2 diabetic adult subjects (above 50 years old) who had uncontrolled (A1c=8-9 %) blood glucose levels with an oral hypoglycemic drug at the screening visit were eligible to participate.

Exclusion criteria

Exclusion Criteria:

Those with type1 diabetes or ketoacidosis, end organ failure as chronic renal failure (estimated serum creatinine level ≥ 1.5mg/dl in male and ≥ 1.4mg/dl in female), liver cell failure (elevated (ALT) and aspartate transaminase (AST) ≥ 2 folds), and heart failure, previous history of pancreatitis, and pregnant or lactating females were excluded from the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Placebo comparator
    Control Group

    35 patients will be given placebo (only adjust their drugs to control blood glucose level)

    Drug: Control group

  • Experimental
    DPPI Group

    35 T2DM patients will be given DPP4Is once or twice daily

    Drug: DPP-4 inhibitor group

  • Experimental
    DPPI + metformin group

    35 T2DM patients will be given DPP4Is + metformin once or twice daily

    Drug: DPP-4 inhibitor + metformin group

Interventions

06

What researchers measure

Primary outcomes

  1. Serum Inflammatory mediators; TNF-α

    ELISA kits

    Time frame: Before and post 6 month of treatment

  2. MMSE score

    Validated questionnaire assessing the Estimation of Mini Mental State The MMSE has a maximum score of 30 points. The scores are generally grouped as follows: 25-30 points: normal cognition 21-24 points: mild dementia 10-20 points: moderate dementia Examination (MMSE) score

    Time frame: Before and post 6 month of treatment

  3. PHQ-9

    Validated questionnaire assessing patient mental health and depression PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression.;

    Time frame: Before and post 6 month of treatment

  4. serum amyloid-β

    Time frame: Before and post 6 month of treatment

Secondary outcomes

  1. Serum Insulin

    ElISA kits

    Time frame: Before and post 6 month of treatment

  2. Serum fasting and 2-he post prandial glucose

    Time frame: Before and post 6 month of treatment

  3. HOMA-IR

    Time frame: Before and post 6 month of treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Jun 2024, 6 months later.

Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's planned 6 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 11, 2023
StartEst.
Dec 30, 2023
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jul 15, 2024
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06164535
Collaborators
Clinical Pharmacy Department, Faculty of Pharmacy, 6 October University, Faculty of Medicine, Minia University
Responsible party
Asmaa Abdelfattah Elsayed (Lecturer of clinical pharmacy, Beni-Suef University) — Principal investigator
First posted
Dec 11, 2023
Start date
Dec 30, 2023 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Jul 15, 2024 (estimated)
Last update
Dec 11, 2023

Study contacts

Asmaa Elsayed
Contact
asmaa.abdelfattah@pharm.sohag.edu.eg
+201095727201
Engy Wahsh
Contact
engywahsh@o6u.edu.eg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: DPP-4 inhibitors · Metformin

Start the discussion